Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Patient Resources
COVID-19 Patient Resource Center
Clinical Trials
Search Clinical Trials
Patient Notification System
What is Clinical Research?
Volunteering for a Clinical Trial
Understanding Informed Consent
Useful Resources
FDA Approved Drugs
Professional Resources
Research Center Profiles
Clinical Trial Listings
Market Research
FDA Approved Drugs
Training Guides
Books
Events
Newsletters
JobWatch
White Papers
Patient Education
SOPs
eCFR and Guidances
White Papers
Trial Listings
Advertise
COVID-19
iConnect
Sign In
Create Account
Sign Out
My Account
Home
» FDA Releases Draft Guidance for Dry Eye Drugs
Looking to read the full article? Subscribe today!
FDA Releases Draft Guidance for Dry Eye Drugs
January 5, 2021
Sponsors looking to develop drugs to treat dry eye should consider using both traditional environmental exposure and challenge-model trials, according to an FDA draft guidance released last month.
Upcoming Events
26
Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27
Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
11
Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
23
Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
26
Apr
MAGI's Clinical Research vConference — Spring 2021
Featured Products
Regenerative Medicine: Steps to Accelerate Development
Clinical Trial Agreements: A Guide to Key Words and Phrases
Featured Stories
Pace of Technology Innovation in Trials Could Slow After Pandemic Eases
Ask the Experts: Certifying and Maintaining Copies of Original Source Documents
Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources
Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
The information you need to adapt your monitoring plan to changing times.
Learn More Here